Response and tolerance study of a novel nonspecific antiinflammatory drug meloxikam (movalis) in patients with osteoarthrosis (OA).
630 OA patients entered a multicenter trial in 29 hospitals. Movalis was given in a dose 7.5 mg or 15 mg (groups 1 and 2, respectively). In poor response the dose 7.5 mg was raised to 15 mg. The course of treatment took 2-4 weeks. The effect was assessed in scores by changes in the complaints.
Movalis has a significant antiinflammatory and analgetic effect, improved joint function, diminished severity of arthralgia and synovitis. Side effects were occasional.
Movalis introduction in wide rheumatological practice will raise effectiveness of OA treatment and reduce the risk of side effects.